Evaluation of cell lines producing a monoclonal antibody, and production and characterization of a cgmp master cell bank
Ended Awarded Last action
- Contract number
- 75N93022F00001
- Awardee
-
Dynport Vaccine Company LLC UEI LXNEGTYDR755 Part of General Dynamics Corp
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,213,178
Award facts
- Contract value 100% obligated
- $1,213,178.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $369,715 | |
| Other Administrative Action | $0 | |
| Original award | $843,463 |
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.2 million delivery order contract to Dynport Vaccine Company LLC DVC Segment Division for the evaluation of cell lines producing a monoclonal antibody, and production and characterization of a cGMP master cell bank. Dynport Vaccine Company LLC DVC Segment Division, a subsidiary of General Dynamics Corp., will perform this work under its Preclinical Services for Biopharmaceutical Product Development master indefinite-delivery/indefinite-quantity contract. KBI Biopharma Inc., doing business as K B I Biopharma, was selected as a subcontractor to provide services in support of this contract. The period of performance is from July 20, 2022 through August 18, 2023 in Fort Detrick, Maryland.
Quick answers
Who was awarded contract 75N93022F00001?
75N93022F00001 was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 20, 2022.
How much is contract 75N93022F00001 worth?
The government has obligated $1,213,178 on 75N93022F00001.
Is contract 75N93022F00001 an order under another contract?
Yes. 75N93022F00001 is a delivery order under HHSN272201600005I, an indefinite delivery contract, on Preclinical Services for Biopharmaceutical Product Development.
Was contract 75N93022F00001 competed?
The extent of competition for 75N93022F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award